In a rare and surprising reversal, the Food and Drug Administration gave Amicus Therapeutics Inc. the greenlight Tuesday to submit its rare-disease drug, Galafold, for an accelerated review process. That’s despite the agency previously saying that the drug maker needed to run another clinical trial to better evaluate side-effects—which it hasn’t—before the agency would consider reviewing the drug.

The reversal is raising eyebrows—and stocks—amid speculation that the FDA’s about-face on Galafold was political and a sign of easier times for the makers of lucrative rare-disease drugs.

Central to that speculation is a meeting back in February between President Trump and Amicus’ CEO , John Crowley, STAT reports. Crowley got the president’s ear following the FDA’s request for more data last year, which spurred Crowley to publicly campaign for the FDA to lower its standards for bringing drugs for rare diseases to market.

Amicus had been developing Galafold for more than a decade to treat Fabry disease, a genetic condition that causes systemic, life-threatening complications from a specific type of fat building up in the body’s cells. The disease affects about one in 40,000 to 60,000 people. Galafold earned approval in Europe, but the FDA said last year that Amicus needed a new trial to flesh out some troubling gastrointestinal issues.

Amicus’ stock plummeted following the news, and Crowley was angered. After he spoke with Trump in February, the president vowed in his first address to Congress to “slash restraints” to treating rare diseases. In making the point, Trump referenced Crowley’s daughter, who suffers from a rare disorder called Pompe disease. In March, Crowley went on to lambast the FDA for requiring “yet another study” in an opinion piece published in the Observer, which was formerly owned by Trump’s son-in-law Jared Kushner.

Crowley disputes that his appeal to Trump prompted the FDA’s turnabout on Galafold. “I don’t believe at all politics played a role in this,” he told STAT. He points to the 21st Century Cures Act, crafted during the Obama era, as a driving force.

Regardless, other rare-disease drug makers and their investors are salivating over the reversal, Bloomberg reports. At the hint of a political shift, Amicus’ shares jumped 26 percent following the news, and other pharmaceutical companies with rocky FDA relations also climbed. Those include PTC Therapeutics Inc, which is forcing an FDA review over the agency’s objections that its drug for a rare muscle-wasting disease failed a Phase III trial.

Getting a drug to market is obviously good for a company’s bottom line, but marketing a rare-disease drug that has little or no competition—aka, an orphan drug—can be especially good. As notorious ex-pharmaceutical CEO Martin Shkreli noted in his pitches to investors , companies can make a lot of money from orphan drugs because you can charge patients with rare diseases more money. Orphan drugs also earn companies longer exclusivity periods.

Bloomberg points out that a recent analysis by life-science data company Evaluate LLC found the average per-patient costs for an orphan drug in 2016 was $140,443, while costs for non-orphan drugs averaged just $27,756 per patient. Galafold’s list price in Europe is $260,000 a year.

Just because Galafold will now get an FDA review does not mean it will get approval—or that other drug makers will have an easier time. But it does signal that for some reason, the FDA suddenly sees the same data as stronger now than last year. Crowley is hopeful that Galafold will be on the market by the second half of 2018.